Pregnancy and venous thromboembolism

  title={Pregnancy and venous thromboembolism},
  author={Eleonora Ralli and Luigi Zezza and Donatella Caserta},
  journal={Current Opinion in Obstetrics and Gynecology},
Purpose of review This review provides a concise and complete overview of diagnostic work-up and treatment of venous thromboembolism in pregnancy, with attention to recent research developments and recent applicable guidelines. This may be useful for all the players of the multidisciplinary interaction needed in this disease management, namely cardiologists and gynecological/obstetric teams. Recent findings Venous thromboembolism is, in the developed world, a major cause of maternal morbidity… 
4 Citations

Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis.

It is encouraging to note that the published data to date regarding Asian patients indicates that such new therapies are safe and efficacious, and efforts to improve outcomes in patients with DVT rely on the awareness in the scientific and medical community regarding the importance of DVT.

Overcoming challenges of venous thromboembolism in sickle cell disease treatment

ABSTRACT Introduction: Venous thromboembolism (VTE) is a common comorbid condition found in sickle cell disease (SCD) and is associated with increased mortality for adults with SCD. The

[Renal vein thrombosis in the puerperium: case report].

This study reported a case of renal vein thrombosis in the puerperium, and described the clinical case, risk factors, diagnostic methods, and treatment instituted.

Origin and levels of circulating microparticles in normal pregnancy: A longitudinal observation in healthy women

Microparticles convey prothrombotic and proinflammatory antigens already from the first trimester of normal pregnancy, which may contribute to the global hypercoagulable state observed, particularly in the last months of pregnancy, also in healthy women.



Venous thromoboembolic disease and pregnancy

Targeted prophylaxis in those considered at increased risk should be offered antenatally with regular reassessment of individual risk throughout pregnancy, and evidence based guidelines are referred to.

Pregnancy and venous thromboembolism.

There is a need for methodologically strong studies in pregnant women, especially with respect to risk stratification, optimal heparin doses, usefulness of anti-FXa levels and their correlation with clinical outcomes, and correct management of anticoagulation during delivery.

Practice bulletin no. 123: thromboembolism in pregnancy.

  • A. James
  • Medicine
    Obstetrics and gynecology
  • 2011
The prevalence and severity of venous thromboembolism during pregnancy and the peripartum period warrant special consideration of management and therapy, including the treatment of acute thrombotic events and prophylaxis for those at increased risk of thromBotic events.

Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.

The effects of thromboprophylaxis in women who are pregnant or have recently given birth and are at increased risk of VTE are assessed, and the risk ratios for symptomatic thromboembolic events and adverse effects of treatment are identified.

Pregnancy-associated venous thromboembolism: prevention and treatment.

  • S. Bates
  • Medicine
    Seminars in hematology
  • 2011
Recommendations for the management and prevention of VTE during pregnancy are provided based largely upon observational studies and from data in nonpregnant patients.

Treatment of venous thromboembolism during pregnancy.

Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study

Pregnancy‐associated venous thrombosis was highly increased in carriers of factor V Leiden or the prothrombin 20210A mutation, and the risk was highest in the third trimester of pregnancy and during the first 6 weeks after delivery.

Risk factors for thrombosis in pregnancy.

Prevention of venous thromboembolism in pregnancy: a review of guidelines, 2000-2011.

There is some agreement between U.S. and international guidelines that women should be assessed for VTE risk during preconception and again in pregnancy, but no agreement exists as to the clinical subgroups for which screening should be done.